Showing results (51-60 of 293) with videos related to
Sort By:
Pageof 30
JBMR Plus|December 17, 2024
Cardiovascular outcomes of romosozumab treatment-real-world data analysisAnat Tsur, Avivit Cahn, Ludmila Levy, et al.Clinical Chemistry|April 17, 2019
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.Cells|April 27, 2026
Inflammation in Target Organs: From the Bench to the ClinicRoni Weinberg Sibony, Itamar RazExpert Opinion on Pharmacotherapy|March 6, 2019
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetesGenya Aharon-Hananel, Itamar RazThe Lancet. Diabetes & Endocrinology|June 9, 2015
New forms of insulin and insulin therapies for the treatment of type 2 diabetesAvivit Cahn, Roberto Miccoli, Angela Dardano, et al.The American Journal of Medicine|November 3, 2015
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1cMatthew A Cavender, Benjamin M Scirica, Itamar Raz, et al.Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.Diabetes Care|July 22, 2016
Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes CouncilOfri Mosenzon, Rena Pollack, Itamar RazTrends in Biotechnology|March 1, 2005
Immune modulation for prevention of type 1 diabetes mellitusItamar Raz, Roy Eldor, Yaakov NaparstekDiabetes/Metabolism Research and Reviews|March 10, 2009
Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial resultsRoy Eldor, Sameer Kassem, Itamar RazPageof 30